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Apolipoprotein D (ApoD) is an ancient member of the lipocalin family with a high degree of sequence
conservation from insects to mammals. It is not structurally related to other major apolipoproteins and
has been known as a small, soluble carrier protein of lipophilic molecules that is mostly expressed in
neurons and glial cells within the central and peripheral nervous system. Recent data indicate that ApoD
not only supplies cells with lipophilic molecules, but also controls the fate of these ligands by modulating
their stability and oxidation status. Of particular interest is the binding of ApoD to arachidonic acid and
its derivatives, which play a central role in healthy brain function. ApoD has been shown to act as a
catalyst in the reduction of peroxidized eicosanoids and to attenuate lipid peroxidation in the brain.
Manipulating its expression level in fruit ﬂies and mice has demonstrated that ApoD has a favorable
effect on both stress resistance and life span. The APOD gene is the gene that is upregulated the most in
the aging human brain. Furthermore, ApoD levels in the nervous system are elevated in a large number
of neurologic disorders including Alzheimer’s disease, schizophrenia, and stroke. There is increasing
evidence for a prominent neuroprotective role of ApoD because of its antioxidant and anti-inﬂammatory
activity. ApoD emerges as an evolutionarily conserved anti-stress protein that is induced by oxidative
stress and inﬂammation and may prove to be an effective therapeutic agent against a variety of neu-
ropathologies, and even against aging.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
A major focus of today’s research in neuroscience is on the mo-
lecularmechanisms leading to age-related neurologic decline. Given
the continuous increase in life expectancy in human populations
worldwide, ﬁnding strategies to maintain health in old age is
becoming amatter of increasing socio-economic relevance (Oeppen
and Vaupel, 2002; Wilmoth, 2000). Age-related disorders are pre-
dicted to have dramatic repercussions for health and social systems
over thenext fewdecades. Aging is themost signiﬁcant risk factor for
cognitive decline and neurodegenerative disorders, a set of pathol-
ogies that has collectively been referred to as the silent epidemic
(Larson, 2001). After the age of 65 years, the incidence and preva-
lence of Alzheimer’s disease (AD) double every 5 years (Kukull et al.,
2002). After the age of 45 years, the incidence of stroke doubleswithmistry, Biocenter, Innsbruck
a. Tel.: þ43 512 9003 70284;
t (R. Schweigreiter).
Inc. Open access under CC BY-NC-NDeach decade (Kelly-Hayes, 2010). Two of the main drivers of age-
related and disease-related neurologic decline seem to be oxida-
tive stress and chronic inﬂammation (Bishop et al., 2010; Salminen
et al., 2012). Both forms of cellular stress increase with age because
of the organism’s declining capacity for maintenance and repair.
Reactive oxygen species (ROS) are inevitably generated by the aer-
obic metabolism, but are controlled in early life by a variety of
antioxidant mechanisms. With increasing age, however, ROS pro-
duction gradually overwhelms these lines of defense, resulting not
only in structural damage tomolecules but also in thedestabilization
of the redox-sensitive signaling pathways and inducement of
inﬂammation. Levels of oxidative stress and inﬂammation are also
elevated in the brain in a number of neurologic and psychiatric
disorders, and aggravate pathogenesis by progressively disrupting
tissue homeostasis (Amor et al., 2010; Federico et al., 2012; Glass
et al., 2010; Reynolds et al., 2007). There is growing evidence that
apolipoprotein D (ApoD) is dispatched as part of the organism’s
natural defense against oxidative and inﬂammatory stress in the
aging and degenerative brain. Although small in size it appears to
have a major impact on brain health. In this paper we review the
evidence for the neuroprotective role of ApoD during aging, and also license.
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explore its potential as a therapeutic agent against a number of
neuropathologies, and even against aging.
2. ApoD
2.1. ApoD: an atypical apolipoprotein
ApoD is a secreted 29-kDa glycoprotein and a member of the
lipocalin family (Rassart et al., 2000). Lipocalins are phylogeneti-
cally old proteins found in prokaryotes and eukaryotes, and their
functional hallmark is the binding and transport of small hydro-
phobic molecules (Grzyb et al., 2006). At a structural level, lip-
ocalins are characterized by a ligand-binding pocket typically
formed by an 8-strand antiparallel beta-barrel and the presence of
up to 3 highly conserved short sequence motifs, known as short
conserved regions (SCRs), within this fold. Lipocalins are sub-
divided on the basis of the number of these SCRs present into core
(or kernel) lipocalins harboring 3 SCRs, and outlier lipocalins with
only 1 or 2 SCRs. ApoD is a kernel lipocalin and has historically
been classiﬁed as an apolipoprotein, the heterogenous group of
lipid-binding proteins present in lipoprotein particles. Although
originally isolated from human plasma high-density lipoproteins
(HDLs) (McConathy and Alaupovic, 1973) ApoD is expressed in a
variety of organs, with high levels of expression being found in the
testes, peripheral nerves, the brain, and the spinal cord. ApoD is
also readily detected in a variety of body ﬂuids. It is most abundant
in plasma, with the concentration in human plasma being
approximately 100 times higher than in human cerebrospinal ﬂuid
(CSF) (Rassart et al., 2000; Terrisse et al., 1998). It is interesting
that the expression of ApoD in rodents seems to be largely
restricted to the central nervous system (CNS) tissue (Rassart et al.,
2000). It is also of note that there are distinct differences between
the composition of lipoprotein particles present in the CSF and that
of lipoprotein particles in the serum, and that ApoD is found in all CSF
lipoprotein classes (Borghini et al., 1995; Koch et al., 2001). Overall,
the expression pattern of ApoD is in striking contrast to that of the
other apolipoproteins, which are mainly produced in the liver and
the intestinal epithelium. Moreover, the ApoD amino acid sequence
does not show any similarity to that of any other apolipoproteins
(except for ApoM, which is a member of the outlier lipocalin sub-
family), but within mammals, it has the highest degree of homology
to the retinol binding protein, RBP4. In view of these peculiarities,
ApoD has been termed an atypical apolipoprotein (Weech et al.,
1991).
Determination of the 3-dimensional structure of ApoD has
conﬁrmed the lipocalin-like beta-barrel fold that forms a cup, or
calyx, with a central cavity serving as a ligand-binding pocket
(Eichinger et al., 2007). Unlike other lipocalins, however, ApoD
has a number of extended loops at the entrance to the ligand
pocket that contain hydrophobic residues. It is through these
exposed hydrophobic side chains that ApoD is believed to be
inserted into the lipid envelope of the HDL particle or cell mem-
branes. In fact, ApoD is not a classical “integral” apolipoprotein
embedded in lipoprotein particles, but rather associates periph-
erally with lipoprotein particles. The physiological orientation of
ApoDmight thus appear to resemble a cup with its opening facing
toward the lipid surface and its base forming a spike that could
interact with a transmembrane receptor (Eichinger et al., 2007).
Exactly which receptor might be involved has not yet been
established; many apolipoproteins have been shown to bind to 1
or more members of the low-density lipoprotein receptor family
(Elliott et al., 2010), but the receptor(s) for ApoD, if any, remain(s)
elusive.The widespread pattern of ApoD expression is reﬂected in a
multitude of possible ligands. While the binding of ApoD to retinol
and retinoic acid, sphingomyelin, progesterone, arachidonic acid
(AA), and anandamide has been conﬁrmed by independent studies
and found to lie in the low micromolar or sub-micromolar range,
there are discrepancies with regard to the interactions between
ApoD and palmitic acid, cholesterol, ß-estradiol, pregnenolone,
bilirubin, and the axillary odorant E-3M2H (Morais Cabral et al.,
1995; Rassart et al., 2000; Ruiz et al., 2013; Vogt and Skerra, 2001).
These controversial data could possibly be explained by technical
issues, such as whether ApoD was prepared as a bacterial recombi-
nant protein or puriﬁed from native sources. Alternatively, some
interactions may be weak because of low afﬁnity binding of ligands
to the exposed hydrophobic residues at the surface of the binding
pocket, or theymay simply be indirect interactions, such as has been
suggested for cholesterol which can be associated with sphingo-
myelin and hence cotransported with ApoD (Ruiz et al., 2013). Mo-
lecular dynamics analyses suggest that binding of AA and its
derivatives toApoDoccurs in a ratherﬂexiblemanner at the opening
of the ligand binding pocket of ApoD and relies on some exposed
hydrophobic residues (Oakleyet al., 2012). The principal binding site
of AA in ApoD thus seems to differ from the binding site of proges-
terone, which was shown to lie deeply buried in the binding pocket,
as revealed by crystallography (Eichinger et al., 2007).
There is increasing evidence that the function of ApoD extends
well beyond the simple transport of lipophilic molecules, and that it
has direct relevance to healthy brain function. ApoD has recently
been demonstrated to catalyze the reduction of hydroperoxides of
AA (i.e., eicosatetraenoic acid) to lipid hydroxides via a highly
conserved methionine residue (Bhatia et al., 2012). Speciﬁcally,
human ApoD has been shown to reduce peroxidized, potentially
radical-generating hydroperoxy eicosatetraenoic acids to the non-
reactive hydroxide forms, thereby preventing lipid peroxidation
chain reactions. This ﬁnding could readily explain the observed
increase in lipid peroxidation in the ApoD knockout mouse brain,
which occurs together with a decreased resistance to oxidative
stress (Ganfornina et al., 2008). Overexpression of human ApoD in
themouse has, in contrast, been shown to result in reduced levels of
lipid peroxidation and increased resistance to oxidative stress
(Ganfornina et al., 2008). It is of note that ApoD was recently
identiﬁed as a major cardioprotective protein in a mouse model of
myocardial infarction. Overexpression of ApoD reduced the rate of
myocardial infarction and protected cardiomyocytes from hypoxia
and/or reperfusion-related stress, a protective effect that was
shown to depend on ApoD’s antioxidant activity (Tsukamoto et al.,
2013).
ApoD may not only act as an antioxidant, with a focus on the
eicosanoid metabolism, but it may also inﬂuence inﬂammatory
pathways. The ratio of peroxidized to reduced eicosanoids is known
to regulate the synthesis of downstream inﬂammatory leukotrienes
(Phillis et al., 2006). Moreover, in a mouse model of viral infection,
overexpression of human ApoD has been shown to reduce T-cell
inﬁltration into the CNS, to decrease production of pro-
inﬂammatory cytokines including IL-1ß and TNFa, and to down-
regulate the activity of phospholipase A2 (PLA2) (Do Carmo et al.,
2008). Because PLA2 is the enzyme that releases AA from mem-
brane phospholipids, ApoD may thereby restrain the availability of
free AA, which is the major precursor of leukotrienes and prosta-
glandins, 2 groups of potent inﬂammatory modulators (Calder,
2005). ApoD also appears to stabilize membrane-associated AA
and attenuate its release from phospholipids. Once released, ApoD
might trap free AA by sequestration and prevent its subsequent
conversion into pro-inﬂammatory eicosanoids, or its peroxidation
to highly toxic compounds (Thomas et al., 2003b).
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molecules but also to actively interfere with their metabolism and
signaling in an antioxidant and anti-inﬂammatory manner.2.2. Phylogeny of ApoD
Lipocalins are ancient proteins and ApoD belongs to the most
ancient group of lipocalins. Genome mining and sequence com-
parisons support the view that lipocalins arose in gram-negative
bacteria and were passed on to primordial eukaryotes by horizon-
tal gene transfer (Bishop, 2000). From there they spread into
present-day plant, metazoan, and “protist” phyla. Lipocalins have
undergone a remarkable radiation in chordates and in particular in
mammals, with 21 lipocalin genes having been described in
humans (http://www.uniprot.org/). In contrast, only a small num-
ber of lipocalins have been identiﬁed in arthropods (e.g., Drosophila
melanogaster), “protists” (e.g., Dictyostelium discoideum), and plants
(e.g., Arabidopsis thaliana), and they have apparently been lost
completely from taxa such as nematodes (Caenorhabditis elegans)
and fungi (Saccharomyzes cerevisiae) (http://www.uniprot.org/).
Phylogenetic analyses based on gene structure and protein
sequence have invariably revealed that ApoD is at the base of the
chordate lipocalin tree. ApoD is thus the earliest lipocalinwithin the
chordate lineage. The other lipocalins were derived from early
ApoD in a monophyletic manner during the course of chordate
diversiﬁcation through multiple gene and genome duplication
events, with RBP4 being the closest paralog of ApoD (Sanchez et al.,
2003; Wang et al., 2007). Matching its status as the primordial
chordate lipocalin, ApoD seems to be a genuine ortholog of the
arthropod lipocalins Lazarillo from the grasshopper Schistocerca
americana (Ganfornina et al., 1995), and the 2 Lazarillo proteins in
D. melanogaster, Glial-Lazarillo (GLaz), and Neural-Lazarillo (NLaz)
(Sanchez et al., 2000) (Fig. 1). The protein sequence of human ApoD
is 25.2% identical to GLaz, 31.3% identical to NLaz, and 26.0% iden-
tical to Lazarillo. When chemically similar amino acids are included
in the alignment, the sequence identity between human ApoD and
its insect orthologs is well above 50%. In contrast, the sequenceFig. 1. ApoD is a lipocalin that has been evolutionarily conserved from insects to
mammals. The secondary structure and sequence elements of human ApoD are
compared with those of the Drosophila Lazarillo proteins, GLaz, and NLaz. The back-
bone of all 3 proteins is comprised of 8 beta sheets (arrows) that give rise to a barrel-
like shape, which constitutes the ligand-binding pocket and is characteristic for lip-
ocalins. This fold is stabilized by 4 conserved cysteine residues forming 2 disulﬁde
bridges. All 3 orthologs have a signal peptide at their N-terminus (not shown) and a
short alpha helix at the C-terminus (cylinder). While the highest sequence conserva-
tion is found in the beta sheets, the sequence stretches in between often contain hy-
drophobic residues which in human ApoD were shown to be organized as protruding
loops framing the entrance to the binding pocket (Eichinger et al., 2007). These hy-
drophobic loops (blue) are assumed to be involved in deﬁning the ligand speciﬁcity
and also to facilitate the interaction of ApoD and Lazarillo proteins with hydrophobic
surfaces. Lazarillo proteins in fact associate with membranes through a GPI-anchor
(yellow bars), whereas human ApoD, but not the ApoD orthologs of other species,
was found to be covalently linked to ApoA2 through a disulﬁde bridge. Met93 in hu-
man ApoD has been shown to have reducing activity and to prevent peroxidation of
lipids. This methionine residue seems to be restricted to ApoD orthologs in higher
vertebrates (mammals and birds). Abbreviation: ApoD, apolipoprotein D.identity between human ApoD and its closest paralog, human RBP4,
is only 23.0% (http://www.uniprot.org/).
This highdegree of sequence conservationbetweenhumanApoD
and its insect orthologs is reﬂected in an evolutionarily conserved
functionality. As is the case with ApoD, the insect Lazarillo proteins
arepredominantlyexpressed in thenervous system.AswithApoD in
the mouse (Ganfornina et al., 2008), GLaz has been implicated in
resistance against oxidative stress in Drosophila (Sanchez et al.,
2006; Walker et al., 2006). Intriguingly, overexpression of human
ApoD in Drosophila both increases stress resistance and extends life
span (Muffat et al., 2008), reproducing the phenotype obtained by
overexpression ofGLaz inDrosophila (Walker et al., 2006). ApoDand
GLaz are thus functionally interchangeable across phyla. Although
the overall structure and function of ApoD has been well preserved
over large evolutionary distances, the protein sequence of ApoD
continues to be varied. For example, unlike all other ApoDorthologs,
humanApoD has a cysteine residue in the hydrophobic region at the
entrance to the ligand-binding pocket, which forms an intermolec-
ular disulﬁde bond with the HDL-associated apolipoprotein A2
(Yang et al., 1994) (Fig. 1). Although the functional consequences of
this covalent interaction are not yet fully understood, this observa-
tion suggests that the association of ApoDwithHDL ismore stable in
humans than any other species.
3. ApoD in the aging brain
3.1. Oxidative stress and inﬂammaging are major drivers of aging
in the brain
3.1.1. Evolutionary biology of aging
Biological aging has been deﬁned as the persistent decline in
Darwinian ﬁtness over an organism’s typical lifetime because of
internal physiological deterioration (Rose,1991). Because individual
organismal ﬁtness is determined by survival and fertility, this
deﬁnition implies that both the chances of survival and the degree
of fecundity of a species shrink with increasing age until they reach
zero at the end of the species’maximum life span. At the ﬁrst glance
this might seem counter-intuitive to the concept of natural selec-
tion since aging, with death occurring at the end of this process, is
clearly bad for the individual but does not seem to be a necessary,
inevitable phenomenon of simple wear-and-tear, as illustrated by
the immortality of the germ line.Why then do somatic cells age, but
not germ cells? An explanation is provided by the evolutionary
theory of aging, and in particular the disposable soma theory
(Kirkwood, 2005; Kirkwood and Austad, 2000; Kirkwood and Rose,
1991). The essence of this theory is that during an individual’s
lifetime there is a trade-off between short-term beneﬁts at a young
age and long-term survivorship. The theory is based on the reali-
zation that organisms have a ﬁnite metabolic energy budget that
must be allocated among somatic maintenance, that is, survival and
reproduction. Investment in somatic maintenance and repair re-
quires metabolic resources that are then not longer available for
reproduction, and vice versa. An optimal resource allocation
therefore evolved in the form of hard-wired genetic programs that
maximize the ﬁtness of an individual. An important aspect of this
solution is the clear-cut separation of an organism’s cell mass into
germ cells and somatic cells. Because the germ cells are far fewer in
number than the somatic cells, an increased investment in main-
tenance and repair of germ cells is affordable to the organism
resulting in their indeﬁnite physiological homeostasis. The soma,
on the other hand, invests more metabolic energy in competitive
reproduction, at the expense of maintenance and repair, therefore
accumulating damage and ﬁnally succumbing to wear-and-tear.
Two major questions that arise from this theoretical framework
are (1) what is the nature of the damage inﬂicted on an organism’s
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have evolved to contain this progressive damage, but which appar-
ently are inadequate in the soma because of metabolic energy limi-
tations? Answering these questions could pave the way for some
genetic engineering aimed at abolishing aging or, at least, delaying
the appearance of age-related and damage-induced pathologies.
At the molecular level, a number of mechanisms have been
identiﬁed that are believed to underlie the damage-induced aging
process including somatic mutations, telomere shortening, protein
denaturation and aggregation, and oxidative stress (Zglinicki,
2003). Each of these stressors can, in theory, be counterbalanced
by the cell: an array of DNA repair enzymes removes molecular
lesions from nucleotides, the telomerase restores the ends of
chromosomes, proteins are stabilized by chaperones and if irre-
versibly denatured, removed and recycled by the proteasome or
autophagosome, and ROS are neutralized by numerous antioxi-
dants. The relative contribution of each of these stressors to the
aging process remains unclear, as does the effectiveness and
metabolic cost of the cellular stress response and repair pathways
(Haigis and Yankner, 2010). The extent and type of damage that the
soma suffers over a lifetime is presumably not homogenous for all
parts of the body, but depends signiﬁcantly on the type of tissue
and its cellular and molecular speciﬁcs.
3.1.2. Oxidative stress and inﬂammaging in the aging brain
Because most of the cells in a brain are postmitotic, telomeric
shortening is not considered likely to be a major cause of aging, but
oxidative stress is likely to play a major role. Firstly, the (human)
brain is the organ with the highest energy demand and the highest
adenosine triphosphate (ATP) production in the body (Kety, 1957;
Sokoloff, 1960). ATP production in mitochondria by oxidative
phosphorylation is, in turn, the main source of ROS. Secondly, the
brain is the most lipid-rich organ in the body (McIlwain and
Bachelard, 1985) and because lipids are a prime target of ROS, the
brain is prone to lipid peroxidation, resulting in membrane
disruption and eventually in the generation of toxic and mutagenic
compounds such as malondialdehyde and 4-hydroxynonenal.
Moreover, in contrast to oxidative protein and DNA damage, lipid
peroxidation proceeds through a self-propagating chain reaction
mechanism that spreads the damage and requires antioxidants for
its termination (Esterbauer, 1993; Gueraud et al., 2010; Marnett,
1999; Yin et al., 2011).
The idea of ROS being essential drivers of aging was ﬁrst
formulated by Denham Harman and became known as the “Free
Radical Theory of Aging” (Harman, 1956). The theory considers ROS
to be inevitable by-products of aerobic metabolism, aggressively
reacting with and thereby damaging cellular macromolecules.
Because of inadequate antioxidant defense mechanisms, macro-
molecular damage accumulates and eventually leads to age-
dependent physiological decline. Although this hypothesis of
ROS-induced aging based on structural damage has received a great
deal of experimental support over the last few decades, more recent
data, in particular from transgenic mouse models, have cast some
doubt over its relevance (Lapointe and Hekimi, 2010; Muller et al.,
2007; Speakman and Selman, 2011).
A new hypothesis on ROS-induced aging, termed the “redox
stress hypothesis”, has recently been put forward by Sohal and Orr
(2012). This new hypothesis shifts the focus from ROS-induced
structural damage to ROS-triggered disruption of the redox-
regulated signaling pathways. In essence, it is based on the reali-
zation that the catalytic or regulatory activity of a variety of proteins
involved in basic signaling pathways, such as, for instance, Ras or
MEKK1, is modulated by the oxidation and/or reduction reactions of
speciﬁc cysteinyl thiol groups (Brandes et al., 2009; Klomsiri et al.,
2011; Winterbourn and Hampton, 2008). With increasing age, aprogressive ROS-induced pro-oxidative shift is assumed to occur in
the cellular redox state, leading to the over-oxidation of redox-
sensitive proteins and to the subsequent disruption of redox-
regulated signaling pathways.
Another deleterious effect of ROS is the induction of cellular
senescence and inﬂammation (Lu and Finkel, 2008; Naik and Dixit,
2011; Ramsey and Sharpless, 2006). Cellular senescence is a cell fate
similar to apoptosis, differentiation, or proliferation that is char-
acterized by essentially irreversible growth arrest and occurs when
cells experience potentially oncogenic insults including DNA dam-
age, telomeric shortening, protein aggregation, and increased levels
of ROS (Campisi, 2007; Tchkonia et al., 2013). In contrast to
apoptosis, however, cells survive initially but remain locked in a
non-proliferating state, thereby reducing the risk of tumorigenesis.
Senescence has presumably evolved as an alternative to apoptosis
for handling insulted cells. It is evidently a less harsh measure than
apoptosis and the decision between apoptosis and senescence may
depend on the severity of the insult. Because senescent cells are still
metabolically active, tissue homeostasis is preserved for some time
before inﬂicted cells are apparently removed by the immune sys-
tem. For a characteristic of senescent cells is the so-called senes-
cence-associated secretory phenotype (SASP), which refers to the
continued secretion of pro-inﬂammatory cytokines, chemokines,
and proteases (Kuilman and Peeper, 2009; Tchkonia et al., 2013) and
leads to inﬁltration of immune cells for the removal of damaged
cells. Although aimed at resolving local and time-limited tissue
damage, SASP becomes chronic in aged tissue, which because of
continuous exposure to a variety of stressors, is enriched in se-
nescent cells. This age-dependent chronic, low-level inﬂammatory
response has been termed sterile inﬂammation (indicating an
absence of pathogens) or “inﬂammaging”, because of its intimate
relationship with the damage-induced aging process (Franceschi
et al., 2000). Interestingly, inﬂammaging seems to be self-
propagating through a positive feedback loop or vicious cycle. As
indicated previously, oxidative phosphorylation in mitochondria is
the main source of ROS in a cell. ROS-induced damage to mito-
chondria including the mitochondrial DNA is believed to result in
progressively defective oxidative phosphorylation, which in turn
increases ROS production. The rate of mitochondrial ROS produc-
tion tends to increase during aging, particularly in long-lived
postmitotic cell types such as neurons (Sohal and Sohal, 1991;
Wang et al., 2013). This mechanism of self-inﬂicted mitochondrial
damage is aggravated by an age-dependent decline in autophagic
clearing capacity (Cuervo, 2008; Rubinsztein et al., 2011). Auto-
phagy is an ancient housekeeping mechanism that controls cellular
homeostasis by sequestering aggregated proteins and dysfunctional
organelles including mitochondria (in this case referred to as
mitophagy) in vesicles and fusing them with lysosomes for degra-
dation and recycling (Ravikumar et al., 2010). Damaged mito-
chondria consequently accumulate within senescent cells in aged
tissue and produce increasing levels of ROS, thereby triggering an
inﬂammatory response through the SASP. There is, moreover, evi-
dence that damaged mitochondria activate the NRLP3-dependent
inﬂammasome, a protein platform that acts as a sensor of intra-
cellular damage including elevated levels of ROS and elicits an in-
ﬂammatory response (Gross et al., 2011; Zhou et al., 2011). Recent
data suggest that the SASP and the inﬂammasome are tightly linked
in the sense that activation of the inﬂammasome precedes the
implementation of the SASP (Acosta et al., 2013).
Taken together, aging occurs because of a cell’s progressive
inability to cope with various forms of stress. Elevated levels of ROS
are a major stressor in the aging brain, but not the only one. The
main cellular sources of ROS are mitochondria; in a vicious cycle
ROS damage mitochondrial enzymes and mitochondrial DNA such
that even more ROS are generated because of defective oxidative
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through at least 3 distinct mechanisms. First, they inﬂict direct
chemical damage to cellular macromolecules because of their high
reactivity. Second, they disrupt basic redox-sensitive signaling
pathways by shifting a cell’s redox balance to a pro-oxidative state.
Third, elevated ROS induce a senescent state and activate the
endogenous inﬂammasome, with both processes being mechanis-
tically linked and triggering a chronic inﬂammatory response and
subsequent disruption of tissue homeostasis.
3.2. ApoD: a natural defense against age-related stress
In the CNS, ApoD is mainly expressed in white matter, within
neurons, oligodendrocytes, and astrocytes, whereas in the periph-
eral nervous system (PNS) ApoD is mostly detected in Schwann
cells and ﬁbroblasts. Within the brain there are marked regional
differences in ApoD expression. Areas of high ApoD expression
include the prefrontal cortex, the substantia nigra, and the hippo-
campal formation (Elliott et al., 2010; Rassart et al., 2000).
A number of studies have investigated the dynamics of ApoD
expression in the aging brain. A marked increase in the number of
ApoD positive cells, mostly glial cells, has been documented
through immunohistochemistry in the cortex of the aging human
brain (Kalman et al., 2000). ApoD in the human prefrontal cortex
has been shown to be upregulated 6- to 8-fold at the messenger
RNA and protein level between the early postnatal period of life and
an age of 49 years (Kim et al., 2009). In a cross-species comparative
analysis of transcription changes during brain aging, ApoD was
identiﬁed as the most upregulated gene in the aged brain. Specif-
ically, up-regulation of ApoD mRNA in the cortex during aging was
not only conserved between human, macaque, and mouse, but it
was also the strongest upregulation of any gene in each of these 3
species (Loerch et al., 2008). This study conﬁrms previous results
obtained with the mouse, which indicate a global upregulation of
oxidative stress and inﬂammation induced genes in the aging brain
including ApoD (Lee et al., 2000). In a meta-analysis of age-related
gene expression proﬁles that involved 27 datasets from mouse, rat,
and human, ApoD was found to be the most signiﬁcant of the age-
dependent up-regulated genes (de Magalhaes et al., 2009).
As with all correlational studies, the question of cause or
consequence arises. In this case the question is whether the
observed upregulation of ApoD during aging causes, or is a conse-
quence of, the aging process. The answer has been obtained
through a series of experiments on Drosophila and the mouse that
clearly indicated a highly conserved neuroprotective, antioxidant
function for ApoD during aging. First, overexpression of GLaz, an
ApoD ortholog, in Drosophila resulted in an increased resistance to
oxidative stress and a marked extension in life span by 30% (Walker
et al., 2006). Second, an increase in both life span and stress resis-
tance has also been observed as a result of overexpression of
Lazarillo, the grasshopper ortholog of ApoD, in Drosophila. More-
over, Lazarillo has been demonstrated to functionally restore loss of
Drosophila NLaz by rescuing stress resistance in a neuron-speciﬁc
manner (Ruiz et al., 2012). Intriguingly, overexpression of human
ApoD in Drosophila led to a reduction in age-associated lipid per-
oxidation, concomitant with an increase in stress resistance and
longevity (Muffat et al., 2008). Overexpression of human ApoD in
Drosophila thus reproduces the phenotype of overexpression of
GLaz, indicating a physiological role for ApoD that has been highly
conserved over long evolutionary distances. Similar results have
been obtained from a mammalian model organism. When exposed
to acute oxidative stress, themouse brain responds by up-regulating
ApoD (Ganfornina et al., 2008). Upon oxidative stress transgenic
mice overexpressing human ApoD in the brain exhibit a reduced
rate of lipid peroxidation and an improved rate of survival(Ganfornina et al., 2008). Conversely, ApoD loss-of-function resulted
in elevated levels of peroxidized lipids in the mouse brain, together
with increased sensitivity to oxidative stress (Ganfornina et al.,
2008). Loss of GLaz function in Drosophila has been reported to
increase lipid peroxidation and sensitivity to oxidative stress, and to
decrease the life span (Sanchez et al., 2006). In line with these ob-
servations is the ﬁnding that, upon oxidative stress, ApoD stabilizes
dopaminergic circuits in the substantia nigra, presumably by
lowering the load of lipid peroxidation in, and decreasing the in-
ﬂammatory reactivity of, astrocytes (Bajo-Graneras et al., 2011).
Taken together, these results indicate that upregulation of ApoD
is part of an evolutionarily conserved stress response pathway in
the aging brain. By virtue of its antioxidant and anti-inﬂammatory
activity, ApoD protects against the age-associated oxidative stress
that builds up because of increasing ROS levels. ApoD is likely to
achieve these neuroprotective effects by restraining lipid peroxi-
dation and by modulating AA metabolism in an anti-inﬂammatory
manner.
4. ApoD in neurologic disorders
The main determinant of ApoD expression is cellular stress.
Speciﬁcally, ApoD expression has been shown to be induced
through oxidative stress (e.g., H2O2), UV light, and pro-
inﬂammatory lipopolysaccharides and IL-1a (Blais et al., 1994; Do
Carmo et al., 2007). At the cellular level, this regulatory pattern is
reﬂected by potent up-regulation of ApoD upon growth arrest or
senescence, a cellular fate that is brought about by various forms of
stress and inﬂammation (Do Carmo et al., 2002, 2008; Provost et al.,
1991).
Cellular stress and inﬂammation increase gradually during aging,
and consistent upregulation of ApoD in the aging brain is therefore
not surprising. Aside from aging, ApoD is also upregulated in a range
of neurologic disorders including AD and other forms of dementia,
Parkinson’s disease, motor neuron disease, NiemannePick disease,
meningoencephalitis, multiple sclerosis, major depression disease,
bipolar disorder, and schizophrenia, as well as stroke and traumatic
brain injury (Rassart et al., 2000; Sutcliffe and Thomas, 2002).
Although many of these pathologies appear to have genetic risk
factors, their manifestation is often linked to cellular stress and
inﬂammation (Andersen, 2004; Di Carlo et al., 2012; Glass et al.,
2010; Pizza et al., 2011). In fact aging, which is characterized by
elevated levels of stress and chronic inﬂammation, is the primary
risk factor for a number of neurodegenerative diseases including AD
and other forms of dementia, Parkinson’s disease, and major
depression disease. Normal brain aging, thus, often entails pathologic
forms of neurodegeneration and identifying the underlying mecha-
nisms of age-associated neurodegeneration is of utmost societal
importance (Yankner et al., 2008). Upregulation of ApoD appears to
be a shared response occurring in both the aging brain and in the
pathologic, degenerative brain. Given the neuroprotective role of
ApoD in normal brain aging, it is tempting to speculate that it may
also have a beneﬁcial effect under pathologic conditions. We present
in the following sections the relevant evidence for 3 major brain
pathologies: AD, stroke, and schizophrenia.
4.1. ApoD in chronic neurodegenerative disorders: AD
AD is the most common form of dementia (Kandel, 2012). It is a
progressive disease with symptoms that range from mild memory
lapses to loss of speech and self-awareness, apathy, and immobility.
AD is a typical age-related neurodegenerative disease with its
incidence and prevalence doubling every 5 years after the age of 65
years (Kukull et al., 2002). The ultimate cause of AD is a progressive
loss of neurons, mostly in the hippocampus and the cerebral cortex.
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current research on AD centers on 2 basic ﬁndings. First, in an AD-
affected brain, amyloid plaques that consist mainly of insoluble
aggregates of beta amyloid peptides (Aß), a collection of proteolytic
cleavage products of the amyloid precursor protein, are found
around and between neurons. Second, neuroﬁbrillary tangles,
comprised of aggregates of the microtubule-associated tau protein,
accumulate within neurons themselves. What is the cause and
what is the consequence remains amatter of debate, as does exactly
how these protein aggregates are initiated, and how they ultimately
lead to neuronal cell death (Kandel, 2012).
Elevated levels of ApoD mRNA and/or protein have been found
in the CSF, hippocampus, and entorhinal cortex of AD subjects
(Terrisse et al., 1998) and the number of ApoD immunopositive
neurons has been shown to be markedly increased in AD-affected
brains (Belloir et al., 2001; Kalman et al., 2000). In contrast to
other apolipoproteins, ApoD is co-distributed with compact (dense
ﬁbrillar) but not diffuse (amorphous), Aß plaques. ApoD immuno-
positive cells within these plaques appear to be reactive microglia,
suggesting an inﬂammation-induced upregulation of ApoD in AD
(Desai et al., 2005). Alternatively, Aß itself might induce upregu-
lation of ApoD, as has recently been shownwith a hippocampal cell
line (Martinez et al., 2012). It remains unclear whether this in-
duction would be direct or indirect, but it is known that Aß triggers
production of ROS, which may in turn lead to ApoD upregulation
(Butterﬁeld, 2002). A causal link between Aß and expression of
ApoD is also indicated by a mouse model of AD. Speciﬁcally, ApoD
has been demonstrated to be signiﬁcantly upregulated in the brain
of a transgenic mouse with an overexpressed highly amyloidogenic,
that is, Ab producing, form of human amyloid precursor protein. As
is typical for AD, this effect was observed only in aged (26-month-
old), but not young (6-month-old) animals (Thomas et al., 2001c).
While these results do not necessarily imply a neuroprotective role
for ApoD in AD, recent biochemical data do in fact suggest precisely
such a role. As mentioned previously, ApoD has been demonstrated
to reduce lipid hydroperoxides to lipid hydroxides through a highly
conserved methionine residue (Met93 in human ApoD) (Bhatia
et al., 2012). This reaction results in oxidation of the methionine
sulfhydryl to formmethionine sulfoxide (MetSO), and subsequently
to dimerization of ApoD because of structural destabilization by
Met93-SO, as suggested by molecular dynamics simulation (Oakley
et al., 2012). While MetSO is usually reduced back to methionine
sulfhydryl by MetSO reductases, a substantial decline in this
enzymatic activity has been found in AD brains (Gabbita et al.,
1999). If ApoD is to act as an antioxidant in AD one would expect
to ﬁnd elevated levels of the dimeric form, given that the reductive
regeneration is diminished, and this is in fact exactly the case. In the
brains of AD patients ApoD has predominantly been detected as a
dimerized aggregate (Bhatia et al., 2012, 2013). Elevated levels of
lipid peroxidation were measured in the same AD samples, con-
ﬁrming previous results that showed increased lipid peroxidation
in the brain of AD patients (Butterﬁeld and Lauderback, 2002;
Pratico and Sung, 2004). Detailed studies have even revealed
breakdown products of lipid peroxidation in amyloid plaques of AD
brains (Ando et al., 1998), co-localizing with plaque-associated
ApoD (Desai et al., 2005).
Taken together, these data are consistent with a neuroprotective
role for ApoD in AD. The picture that emerges is that increased
oxidative stress in AD promotes lipid peroxidation and elicits
upregulation of ApoD as part of the brain’s stress response. As the
disease progresses, ApoD is used up by ever increasing levels of
peroxidized molecules, a situation that is aggravated by the failure
to regenerate ApoD because of reduced MetSO reductase activity.
Oxidized ApoD accumulates as dimeric aggregates and is eventually
deposited in amyloid plaques, together with peroxidized lipids.It is of note that a series of studies have detected some poly-
morphisms of the human APOD gene that appear to predispose
carriers to AD (Chen et al., 2008; Desai et al., 2003; Helisalmi et al.,
2004; Shibata et al., 2013). However, evidence that certain APOD
variants are a risk factor for AD ismuch less well established than for
the ε4 allele of APOE (Mahley et al., 2006; Strittmatter et al., 1993).4.2. ApoD in acute neurodegenerative disorders: stroke
A stroke is the disruption of brain function because of a lack of
blood supply (Donnan et al., 2008). There are 2 types of stroke:
ischemic stroke, which is caused by obstruction of ﬂow in a blood
vessel; and hemorrhagic stroke, which is caused by the rupture of a
blood vessel in the brain. The large majority of strokes are ischemic
and hemorrhagic strokes are often associated with ischemia in that
part of the brain that was fed by the ruptured artery. Unlike any
other organ, the brain is exceptionally sensitive to reduced levels of
oxygen because it relies entirely on aerobic metabolism. Depriving
the brain of blood and/or oxygen leads to what is called the
ischemic cascade. Falling levels of ATP quickly result in the failure of
ion pumps and a breakdown of ion gradients, which in turn triggers
a series of interrelated events including a release of the excitotoxic
neurotransmitter glutamate, an inﬂux of calcium, and the genera-
tion of ROS. The damage spreads beyond the immediately affected
area and neurons die by apoptosis (Brouns and De Deyn, 2009).
ApoD has been shown to be upregulated following a stroke.
Speciﬁcally, in a strokemodel of the rat, ApoD expressionwas found
to be increased within the ﬁrst 24 hours in post-ischemic peri-
infarct regions, with a further increase 48 hours post-ischemia
(Rickhag et al., 2006). Immunohistochemical studies revealed that
ApoD within the infarct core was markedly upregulated by
degenerating pyramidal neurons, whereas in the surviving and
regenerating peri-infarct region ApoD was localized in mature oli-
godendrocytes where it remained upregulated for more than 1
week (Rickhag et al., 2008). These ﬁndings are in agreement with
those of Franz et al. (1999), who detected an increase in ApoD
expression at the mRNA and protein level in the cortex and hip-
pocampus of the rat 2e14 days after experimental traumatic brain
injury. ApoD expression was even further enhanced relative to
control levels in ischemic rats housed in an enriched environment,
compared with those housed in a standard environment. This extra
upregulation of ApoD under enriched housing conditions corre-
lated with an improved rate of functional recovery (Rickhag et al.,
2008) This observation is of particular relevance to post-stroke
recovery. Recovery from stroke is based on structural and func-
tional remodeling activities, including the recruitment of alterna-
tive neuronal circuits and axonal sprouting (Dancause et al., 2005;
Wieloch and Nikolich, 2006). Post-ischemic recovery has been
shown to be promoted by an enriched environment, which has
been attributed to enhanced dendritic arborization, increased spine
density, and upregulation of genes coding for synaptic proteins and
growth factors (Johansson and Ohlsson, 1996; Nygren andWieloch,
2005). Neurologic recovery also depends on a substantial level of
plasma antioxidant capacity, as shown in Leinonen et al. (2000).
Studies that report on increased levels of lipid peroxidation in
stroke patients (Polidori et al., 1998) and that show a direct corre-
lation between the extent of lipid peroxidation and severity of
neurologic outcome after stroke (Ferretti et al., 2008) underscore
the relevance of oxidative damage in stroke pathogenesis. ApoD is
likely to reduce the load of oxidative stress in this scenario by virtue
of its antioxidant activity. Aside from its antioxidant role during the
acute stroke phase, ApoD is believed to play a beneﬁcial role in the
regenerating phase by providing lipids such as cholesterol or free
fatty acids, thereby facilitating remodeling processes, including
S. Dassati et al. / Neurobiology of Aging 35 (2014) 1632e16421638remyelination. This notion is supported by data obtained from a
lesion model of the sciatic nerve (Ganfornina et al., 2010).
In conclusion, ApoD may exert a neuroprotective inﬂuence in
the acute stroke phase andmay also support neuronal regeneration
and remyelination in the extended post-stroke recovery phase.
4.3. ApoD in psychiatric disorders: schizophrenia
Schizophrenia is a chronic psychiatric disorder characterized by
disruption of mental processing and inappropriate emotional
behavior (Kandel, 2012). Common symptoms include delusions,
illusions, hallucinations, disorganized speech, and ﬂattened or ab-
sent emotional responsiveness. These symptoms are typically
accompanied by social withdrawal or isolation.While the causes for
this disease remain unknown, it appears to result from an interplay
between genetic and environmental factors. There is a large body of
evidence that an imbalance in neurotransmitter activities, with a
special focus on dopamine, can give rise to the symptoms produced
by this disorder, but deregulation of serotonergic and glutamatergic
transmission also seems to be of relevance (Jones and Pilowsky,
2002; Konradi and Heckers, 2003; van Os and Kapur, 2009).
ApoD has been found to be signiﬁcantly upregulated in the brain
of schizophrenic and bipolar subjects. Speciﬁcally, ApoD expression
was selectively increased in the dorsolateral prefrontal cortex and
the caudate, which are the brain regions that are implicated in the
pathogenesis of these neuropsychiatric disorders (Thomas et al.,
2001b). In a more detailed follow-up study, speciﬁc differences in
neuroanatomic sites of ApoD elevation were found between pa-
tients with schizophrenic disorder and those with bipolar disorder
(Thomas et al., 2003a). ApoD levels have also been found to be
signiﬁcantly increased in the plasma of schizophrenic patients,
including ﬁrst-episode patients, with the increase in ApoD pre-
sumably predating the ﬁrst clinical symptoms (Mahadik et al.,
2002).
Apart from its upregulation in well-deﬁned brain areas in
schizophrenia, there is an interesting link between ApoD and clo-
zapine, as well as other atypical neuroleptics. Clozapine is an
atypical antipsychotic drug that has been shown to be effective in
acute and long-term treatment of patients with bipolar disorder
and schizophrenia, in particular of patients who had proved re-
fractory to other antipsychotic treatments (Ciapparelli et al., 2000).
In contrast to typical antipsychotic drugs, which have high afﬁnities
for dopamine receptors, clozapine binds to multiple neurotrans-
mitter receptors. In a study that searched for clozapine-induced
changes in gene expression within the mouse brain, ApoD was
found to increase both at the mRNA and protein level over a period
of 2 weeks of continued clozapine treatment (Thomas et al., 2001a).
Upregulation of ApoD seems to be a distinguishing feature between
typical and atypical neuroleptics because the atypical drugs ris-
peridone and olanzapine increase the expression of ApoD in the
brain as well, whereas haloperidol, a typical antipsychotic drug,
does not (Khan et al., 2003). Because atypical neuroleptics have a
better treatment outcome in terms of improved cognitive perfor-
mance and ameliorated negative symptoms (Bilder et al., 2002),
these observations raise the intriguing possibility that upregulation
of ApoD is a mechanism underlying the beneﬁcial effect of atypical
antipsychotics in the treatment of schizophrenia. Exactly how ApoD
is able to have a positive modulating effect on schizophrenic
symptoms remains uncertain. However, the well-described role
that ApoD plays in the transport and modiﬁcation of lipids may
provide an explanation, because altered membrane phospholipids
are known to be involved in the pathophysiology of schizophrenia
(Berger et al., 2006; Horrobin and Bennett, 1999). AA is of particular
interest, because this fatty acid is a prominent ligand of ApoD
(Morais Cabral et al., 1995), but also because reducedconcentrations of AA and AA-enriched phospholipids have been
measured in the brains of schizophrenic subjects (Arvindakshan
et al., 2003; Skosnik and Yao, 2003). This reduction in AA concen-
tration is consistent with the increased levels of PLA2 activity that
have been detected in the serum and prefrontal cortex of schizo-
phrenic patients (Gattaz et al., 1987; Ross et al., 1999). Moreover,
ApoD has been found to stabilize plasma membrane-associated as
well as free AA and to attenuate its peroxidation to highly toxic
compounds or its metabolic conversion into pro-inﬂammatory ei-
cosanoids (Thomas et al., 2003b). AA is a polyunsaturated omega-6
fatty acid (20:4 n-6). It is abundant in neuronal membranes and,
together with docosahexaenoic acid (DHA; 22:6 n-3), makes up
more than 90% of the polyunsaturated fatty acids in the CNS
(O’Brien and Sampson, 1965; Youdim et al., 2000). Polyunsaturated
fatty acids are key determinants of membrane order and ﬂuidity
and affect the binding and signaling characteristics of membrane
proteins, including ion channels and neurotransmitter receptors
(Luchtman and Song, 2013). They have been implicated in the
pathogenesis of schizophrenia and their neuroprotective potential
as medication is currently being investigated (Horrobin and
Bennett, 1999; Mossaheb et al., 2012; Perica and Delas, 2011).
ApoD may therefore have a protective effect in schizophrenia by
stabilizing AA for use as a membrane building block and preventing
its peroxidation or metabolic conversion with associated delete-
rious consequences. The notion of an AA-speciﬁc role for ApoD in
schizophrenia is supported by the observation that atypical anti-
psychotics, but not typical ones, prevent the decrease of membrane
phospholipideAA levels in schizophrenic patients (van der Kemp
et al., 2012). Like in AD and stroke, oxidative stress and lipid per-
oxidation seem to be part of the pathophysiology of schizophrenia
(Boskovic et al., 2011) and ApoD might exert a positive inﬂuence
because of its overall antioxidant activity.
Of relevance to the possible beneﬁcial role of ApoD in schizo-
phrenia may also be the impact that ApoD has on the endocanna-
binoid system. Anandamide has recently been identiﬁed as a novel,
high afﬁnity, ligand of ApoD (Ruiz et al., 2013). Because the endo-
cannabinoid system is dysregulated in schizophrenic patients
(Zamberletti et al., 2012), it would be very interesting to explore any
functional relationship between ApoD and endocannabinoids, un-
der both physiological and pathophysiological conditions.
In conclusion, ApoD appears to play a neuroprotective role in
schizophrenia, which is further augmented by treatment with
atypical neuroleptics, including clozapine. Elevating the expression
level of ApoD may in fact reﬂect a novel molecular mechanism
underlying the favorable effects of atypical antipsychotics, as
opposed to typical antipsychotics, in schizophrenic patients.
5. Outlook
Characterizing the complete ligand repertoire of ApoD will be
the key to appreciating its full physiological relevance. Anandamide
has only recently been identiﬁed as a novel ApoD ligand, through a
candidate screening approach (Ruiz et al., 2013). Although the
known ligands of ApoD belong to quite different groups of lipophilic
molecules, there is a remarkable speciﬁcity in the binding pattern.
For instance, ApoD binds free AA and anandamide (N-arach-
idonoylethanolamine) with high afﬁnity, but not the chemically
similar 2-arachidonyl glycerol (Ruiz et al., 2013). This makes it
difﬁcult to predict novel ligands. With regard to the length of the
hydrocarbon chain, ApoD has been shown to accommodate C16
(palmitic acid), C18 (sphingosine), and C20 (AA) ligands, each in all-
cis conﬁguration (Morais Cabral et al., 1995; Ruiz et al., 2013). To our
knowledge, there have been no investigations to date into whether
ApoD binds omega-3 fatty acids, in particular a-linolenic acid (18:3
n-3), which is an essential fatty acid, eicosapentaenoic acid (EPA;
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be of considerable interest from a neurologic point of view. Omega-
3 fatty acids, also known as n-3 fatty acids, are vital building blocks
for neuronal membranes and indispensable for the maintenance of
healthy brain function and for regeneration of the injured or
stressed brain. Omega-3 fatty acids become deﬁcient in the aging
and degenerative brain, but dietary supplements have been shown
to restore their membrane levels and to attenuate cognitive decline
(Luchtman and Song, 2013; Yehuda et al., 2002). In this context, it
would also be interesting to investigate any relationship between
ApoD and resolvins, which are derivatives of EPA and DHA,
and neuroprotectins, which are derived from DHA. Both classes of
eicosanoids and docosanoids have been demonstrated to be potent
anti-inﬂammatories and antioxidants and to exert an overall pro-
survival, anti-apoptotic inﬂuence on neurons (Bazan, 2006;
Farooqui, 2012; Ji et al., 2011).
While in chronic disease or aging ApoD is upregulated approx-
imately 2 to 3-fold at the mRNA and protein level, its dynamic range
of expression appears to be far greater. In a peripheral nerve crush
model of the rat, ApoD protein was dramatically induced in the
regenerating nerve, by a factor of 500 (Boyles et al., 1990). The
question that arises is what would be the beneﬁcial effect in AD or
aging if ApoD were upregulated to a similar extent and expression
maintained at that high level for an extended period of time?
Would the progress of the disease or aging be attenuated and
symptoms ameliorated in a clinically relevant manner? After all, in
AD the increase in endogenous ApoD levels may be ineffective as
the dimerized form of the protein that is predicted to lack antiox-
idant activity, is elevated because of high levels of lipid peroxidation
and reduced MetSO reductase activity (Bhatia et al., 2012). More-
over, atypical neuroleptics induce endogenous ApoD and thereby
appear to produce favorable effects in the treatment of psychiatric
diseases. Exogenously added ApoD may therefore attenuate the
progress of a number of neurologic diseases without the deleterious
side effects that have, for instance, been described for antipsychotic
drugs. Although ApoD can be efﬁciently produced as a functional
recombinant protein in microbial host cells, its therapeutic value
for long-term systemic application is restricted by the blood-brain
barrier (Vogt and Skerra, 2001). It might therefore be more prom-
ising to try to induce upregulation of endogenous ApoD. Its pro-
moter has been characterized at some length (Do Carmo et al., 2002;
Levros et al., 2010) but it still remains unclear by which signaling
pathways the dramatic induction as described in (Boyles et al., 1990)
is attained, or how atypical antipsychotic drugs such as clozapine
elevate ApoD expression levels. Switching ApoD expression into
acute injury mode over an extended period of timemay have visible
clinical beneﬁts in a series of neurologic and psychiatric disorders
and could possibly even delay the aging process in the brain.
6. Conclusion
ApoD has initially been characterized as a carrier of a range of
small lipophilicmolecules. It is prominently expressed in the central
andperipheral nervous system,bybothglial cells andneurons. In the
past few years it has become apparent that the function of ApoD is
not merely limited to supplying cells with membrane building
blocks, hormones, and messengers. One of its best characterized
ligand interactions is with AA, which is enriched in the CNS in the
same way as ApoD. It has been demonstrated in a series of studies
that ApoD modulates AA metabolism in an anti-inﬂammatory and
antioxidant manner. This may in part explain why ApoD confers
potent resistance to oxidative stress when overexpressed in
Drosophila or the mouse. Overexpression of ApoD results in an
extension of themean life span in Drosophila and increases survival
under stress in the mouse; the ApoD gene therefore belongs to thesmall selection of genes whose manipulation is life extending.
Conversely, endogenous ApoD is upregulated during aging and un-
der a large variety of neurologic and psychiatric disorders, suggest-
ing that induction of ApoD is part of a basic evolutionarily conserved
anti-stress response. ApoD, thus, appears to be an ancient anti-stress
protein that counteracts cellular stress, and in particular oxidative
stress and inﬂammation. Both forms of stress are widespread
throughout the body and increase with advancing age. Oxidative
stress and inﬂammation are also generated at some point in time,
either directly or indirectly, in most neurologic and psychiatric dis-
orders. Even if ApoD does not target the primary cause of a disorder,
it maywell ameliorate the clinical symptoms and delay the progress
by reducing the stress load that accompanies adisorder. Augmenting
its neuroprotective properties could be particularly relevant for
chronic diseases and aging, which are characterized by a continuous
rate of oxidative and inﬂammatory stress, but exhibit onlymoderate
upregulation of ApoD compared with the dramatic but temporary
elevation of ApoD levels observed in acute injuries. ApoD may
therefore be a promising therapeutic target for a wide range of
neurologic diseases, as well as for aging, because of its anti-stress
activity; designing strategies for its delivery to the CNS for long-
term application, or for manipulating its endogenous expression
levels, will provide a challenge for future research.Disclosure statement
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